{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:58:31Z","timestamp":1761512311704},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.parkreldis.2006.07.010","type":"journal-article","created":{"date-parts":[[2006,10,18]],"date-time":"2006-10-18T12:32:44Z","timestamp":1161174764000},"page":"365-368","source":"Crossref","is-referenced-by-count":12,"title":["Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: A case report of 24 months\u2019 oral substrate reduction therapy with miglustat"],"prefix":"10.1016","volume":"13","author":[{"given":"D.A.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Richfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2006.07.010_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple\u201d disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.parkreldis.2006.07.010_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.WNL.0000072482.70963.D7","article-title":"Gaucher's disease with Parkinson's disease. Clinical and pathological aspects","volume":"61","author":"Bembi","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2006.07.010_bib3","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","article-title":"Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews","volume":"351","author":"Aharon-Peretz","year":"2004","journal-title":"N Engl J Med"},{"issue":"105","key":"10.1016\/j.parkreldis.2006.07.010_bib4","first-page":"4","article-title":"Gaucher disease with Parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to Parkinsonism?","volume":"70","author":"Tayebi","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.parkreldis.2006.07.010_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.parkreldis.2006.07.010_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.parkreldis.2006.07.010_bib7","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.parkreldis.2006.07.010_bib8","first-page":"153","article-title":"The unified Parkinson's disease rating scale","volume":"Vol. 2","author":"Fahn","year":"1987"},{"key":"10.1016\/j.parkreldis.2006.07.010_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10545-005-0585-9","article-title":"Evaluation of three biochemical markers in the monitoring of Gaucher disease","volume":"28","author":"Vellodi","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.parkreldis.2006.07.010_bib10","doi-asserted-by":"crossref","first-page":"43R","DOI":"10.1093\/glycob\/cwi076","article-title":"Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses","volume":"15","author":"Butters","year":"2005","journal-title":"Glycobiology"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802006001611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802006001611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T00:52:08Z","timestamp":1547254328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802006001611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S1353802006001611"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2006.07.010","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}